Related Experiment Video

Updated: Aug 12, 2026

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Real-World Experience of Hepatitis C Treatment With Glecaprevir-Pibrentasvir During Pregnancy

L Madeline McCrary1, Megan R Curtis1, Jeannie C Kelly2

  • 1Division of Infectious Diseases, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|August 11, 2026
PubMed

Insights

Antenatal hepatitis C virus treatment with glecaprevir-pibrentasvir (GLE/PIB) is effective and safe. This study shows all patients achieved a virologic response with no adverse events in mothers or newborns.

Area of Science:

  • Hepatology
  • Maternal-Fetal Medicine
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection in pregnancy poses risks to both mother and child.
  • Current guidelines recommend shared decision-making for antenatal HCV treatment.
  • Limited data exists on the use of glecaprevir-pibrentasvir (GLE/PIB) during pregnancy.

Purpose of the Study:

  • To evaluate the safety and efficacy of prenatal glecaprevir-pibrentasvir (GLE/PIB) treatment for hepatitis C virus (HCV).

Main Methods:

  • A retrospective case series of 14 pregnant patients with HCV who received GLE/PIB.
  • Treatment completion and virologic response rates were assessed.
  • Maternal and neonatal safety outcomes were monitored.

Main Results:

  • Ten patients completed the GLE/PIB treatment regimen.
  • All patients who completed treatment achieved a virologic response by the time of delivery.
  • No significant maternal or neonatal safety concerns were reported during the study period.

Conclusions:

  • Prenatal treatment with glecaprevir-pibrentasvir (GLE/PIB) appears to be a safe and effective option for managing hepatitis C virus (HCV) in pregnant individuals.
  • Further research is warranted to confirm these findings in larger cohorts.

Keywords:
direct-acting antiviralshepatitis Cperinatal infectionspregnancy

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...